研究参保职工可使用医保个人账户资金为本人及家庭成员购买符合条件的商业健康保险产品，推动 医保商保"一站式"结算，支持商业保险公司探索开发疾病预测与干预保险……日前，北京市医保局、金 融监管总局北京监管局等9部门联合发布《北京市支持商业健康保险高质量发展的若干措施》，推出18 条具体举措，从创新商业健康保险产品供给、提升服务能力、优化结算模式等6个领域，支持商业健康 保险高质量发展，更好满足人民群众多元化保障需求。 无独有偶，金融监管总局广东监管局也于日前联合多个部门印发《推动健康保险高质量发展 服务 健康广东建设的指导意见》，绘制广东健康保险发展短期、中期、长期三个阶段工作目标。 北京、广东两地在"十五五"开局之年谋划商业健康保险高质量发展路径，探索构建多层次医疗保障 体系，最终目的是将更多资源投入到提升人民健康素质上，真正地投资于人。 三是满足湾区居民多样化保障需求。广东目前在售健康保险产品数量1.1万款，产品体系丰富、保 障功能全面。以费用报销型医疗险为例，根据群众收入，分层开发百万医疗险、中端医疗险及高端医疗 险，提升对原研药、进口药、创新药的保障能力，满足多层次、多样化医疗保障需求。 四是为产业发展提 ...

Group 1 - The core viewpoint of the news is the introduction of measures by Beijing's healthcare and financial regulatory authorities to support the high-quality development of commercial health insurance [1][2] - The measures encourage innovation in commercial insurance products, including disease prediction and intervention insurance, specific disease insurance for cardiovascular diseases, rare diseases, and innovative drug insurance [1] - There is a push for the development of group health insurance products, commercial nursing insurance, and income loss insurance due to disability, along with support for eligible companies to engage in dividend-type long-term health insurance [1] Group 2 - The initiative aims to enhance collaboration between commercial health insurance and the pharmaceutical industry by establishing a platform for coordinated development [1] - It promotes the establishment of communication mechanisms between commercial insurance companies and innovative pharmaceutical enterprises to facilitate information sharing and demand matching [1] - The measures also encourage the inclusion of reasonably priced innovative drugs and high-value medical devices related to tumors and rare diseases into the insurance coverage, thereby improving the capacity for major disease protection [1] Group 3 - Strengthening regulatory oversight of commercial health insurance is emphasized, including compliance monitoring and addressing violations to maintain market order [2] - The establishment of a statistical monitoring system for commercial health insurance is proposed, focusing on key indicators such as claims expenditure, cost, and profit levels [2] - The goal is to dynamically understand market operations and guide insurance companies to focus on product innovation and cost control for high-quality development [2]

Core Viewpoint - The Beijing Municipal Medical Insurance Bureau and the Beijing Financial Supervision Bureau have jointly issued measures to support the high-quality development of commercial health insurance, emphasizing product innovation and the development of specialized insurance products [1] Group 1: Support for Product Innovation - The measures encourage commercial insurance companies to explore and develop innovative insurance products, including disease prediction and intervention insurance, specific disease insurance for cardiovascular diseases and rare diseases, as well as innovative drug insurance [1] - There is a push for the development of group health insurance products and support for commercial nursing insurance and income loss insurance due to disability [1] - Qualified commercial insurance companies are encouraged to engage in dividend-type long-term health insurance business [1] Group 2: Tailored Insurance Solutions - The measures promote the development of medical insurance products tailored to the needs of foreign personnel in China, streamlining the insurance and claims processes while enhancing health management services [1] - There is encouragement for the development of unique models for commercial health insurance, leveraging artificial intelligence technology in product design and risk control [1]

Core Viewpoint - The Beijing Municipal Medical Insurance Bureau and the Beijing Financial Supervision Bureau have jointly released measures to support the high-quality development of commercial health insurance, focusing on product innovation and data utilization [1][2]. Group 1: Data Utilization and Innovation - The measures propose to advance the development and utilization of medical insurance data, establishing a data-sharing mechanism for medical expenses, health check-ups, and imaging tests, while ensuring data security and compliance [1]. - Medical institutions and pharmaceutical companies are encouraged to provide information on innovative drugs and clinical trial data for commercial insurance companies to aid in product pricing and risk control [1]. Group 2: Support for Product Innovation - The measures support the innovation of commercial insurance products, including disease prediction and intervention insurance, specific disease insurance for cardiovascular diseases and rare diseases, as well as insurance for innovative drugs and clinical liability [2]. - There is encouragement for the development of group health insurance products, commercial nursing insurance, and income loss insurance due to disability, along with support for eligible companies to engage in dividend-type long-term health insurance [2]. - The measures also promote the development of medical insurance products tailored for foreign personnel in China, streamlining the insurance and claims processes while enhancing health management services [2]. Group 3: Development of Inclusive Health Insurance - The measures aim to enhance the development of inclusive health insurance in Beijing by optimizing product protection levels and service rights, dynamically adjusting special drug lists, and strengthening support for innovative drugs and devices [2]. - There is an exploration of improving product sales mechanisms to better leverage the supplementary protection function of inclusive commercial health insurance [2].

Core Viewpoint - The document outlines measures to promote the high-quality development of commercial health insurance to support innovation in the biopharmaceutical industry in Shanghai [1] Group 1: Commercial Health Insurance Development - The measures aim to enrich the forms of commercial health insurance products [1] - There is a focus on optimizing city-customized medical insurance products, creating region-specific "Shanghai" series health insurance products [1] - The initiative includes enhancing the "Shanghai Huibao" program, supporting the inclusion of innovative drugs and medical devices in coverage [1] Group 2: Coverage and Accessibility - The measures encourage the development of health insurance products that cater to different groups and cover more innovative drugs and medical devices [1] - The initiative aligns with the reform of medical insurance payment methods, aiming to include reasonable medical expenses within commercial health insurance coverage [1] - The goal is to provide citizens with more convenient and autonomous protection services [1] Group 3: Disease Prevention - There is encouragement to explore the development of disease prediction and intervention insurance to reduce the incidence of prevalent diseases [1]

Core Viewpoint - The Shanghai Financial Regulatory Bureau, in collaboration with various governmental departments, has issued measures to promote the high-quality development of commercial health insurance, aiming to support innovation in the biopharmaceutical industry [1][4]. Group 1: Measures Overview - The measures consist of five main areas and eighteen specific actions, including the construction of a multi-tiered commercial health insurance product system and the enhancement of service capabilities [1]. - There is a focus on expanding the coverage of commercial health insurance products, particularly in nursing insurance, and integrating innovative drugs and medical devices into the coverage [1][4]. Group 2: Targeted Populations - The measures encourage the development of health insurance products tailored to specific groups, such as the elderly and those with pre-existing conditions, to enhance insurance coverage for these populations [2]. - Collaboration between insurance institutions and the health industry is emphasized to improve the accessibility and affordability of innovative drugs [2]. Group 3: Service Optimization - The measures propose strengthening the health service capabilities of insurance institutions and expanding services from post-claim to proactive health management [2]. - Encouragement is given for partnerships between insurance companies and healthcare providers to enhance preventive care and chronic disease management [2]. Group 4: Innovation and Data Sharing - The measures advocate for the establishment of a "regulatory sandbox" to pilot innovative health insurance products, ensuring compliance and sustainability [3]. - There is a call for improved data sharing mechanisms among medical, insurance, and pharmaceutical sectors to support product design and risk assessment [3]. Group 5: Payment Mechanisms - The measures suggest innovating payment mechanisms for innovative drugs, involving multiple stakeholders such as insurance, charity organizations, and pharmaceutical companies [4]. - The goal is to facilitate the clinical application of innovative drugs and ensure they are included in insurance coverage without affecting basic medical insurance metrics [4].